IPH-2101
As of the edition of 20 October 2026, IPH-2101 is a drug: went quiet in 2013; acts on KIR2DL1, KIR2DL2 and KIR2DL3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2013
- Kind
- Unknown
- Registered trials
- 4, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innate Pharma | Lead sponsor of trials | 2007 to now |